Akili, Inc.(AKLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKLI Akili, Inc.

Halted 12-24 08:17:53 EST

0.4320

+0.0000

0.00%

High0.4320	Low0.4320	Vol0.00
Open0.4320	D1 Closing0.4320	Amplitude0.00%
Mkt Cap34.01M	Tradable Cap9.30M	Total Shares78.73M
T/O103.05K	T/O Rate0.00%	Tradable Shares21.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AKLI","market":"US","secType":"STK","nameCN":"Akili, Inc.","latestPrice":0.432,"timestamp":1719864000000,"preClose":0.432,"halted":3,"volume":0,"delay":0,"floatShares":21516289,"shares":78726725,"eps":-0.619915,"marketStatus":"Halted","change":0,"latestTime":"12-24 08:17:53 EST","open":0.432,"high":0.432,"low":0.432,"amount":103048.74598846,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.619915,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735050600000},"marketStatusCode":1,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":0.432,"volumeRatio":0},"requestUrl":"/m/hq/s/AKLI/wiki","defaultTab":"wiki","newsList":[{"id":"2448150099","title":"Akili’s Acquisition by Virtual Therapeutics and Nasdaq Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2448150099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448150099?lang=en_us&edition=fundamental","pubTime":"2024-07-02 22:22","pubTimestamp":1719930128,"startTime":"0","endTime":"0","summary":"An announcement from Akili (AKLI) is now available. Akili, Inc. recently completed a significant corporate transaction when it was acquired by Virt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akilis-acquisition-by-virtual-therapeutics-and-nasdaq-delisting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akilis-acquisition-by-virtual-therapeutics-and-nasdaq-delisting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TQQQ","NDAQ","BK4167","BK4139","BK4588","PSQ","QID","LENZ","LU2210150020.SGD","QLD",".IXIC","SQQQ","BK4112","LU2095319765.USD","LU2210149790.SGD","QQQ","NQmain","MNQmain","AKLI"],"gpt_icon":0},{"id":"2444546551","title":"BRIEF-Akili Announces FDA Authorization Of Endeavorotc, The First FDA Clearance Of A Digital Treatment For Adults With Adhd Through A Video Game","url":"https://stock-news.laohu8.com/highlight/detail?id=2444546551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444546551?lang=en_us&edition=fundamental","pubTime":"2024-06-19 04:59","pubTimestamp":1718744385,"startTime":"0","endTime":"0","summary":"June 18 (Reuters) - Akili Inc   :   * AKILI ANNOUNCES FDA AUTHORIZATION OF ENDEAVOROTC, THE FIRST FDA CLEARANCE OF A DIGITAL TREATMENT FOR ADULTS WITH ADHD THROUGH A VIDEO GAMESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKLI","BK4167","ABVC"],"gpt_icon":0},{"id":"2444695463","title":"Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2444695463","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444695463?lang=en_us&edition=fundamental","pubTime":"2024-06-19 04:36","pubTimestamp":1718742985,"startTime":"0","endTime":"0","summary":"Akili (AKLI) said Tuesday its video game app, EndeavorOTC, has received a clearance from the US Food and Drug Administration as an over-the-counter treatment for adults with attention-deficit/hyperact","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","LU0211328371.USD","LU0640476718.USD","LU0127658192.USD","LU0310800965.SGD","ABVC","BK4503","GOOG","LU0079474960.USD","IE0034235188.USD","LU1489326972.SGD","AAPL","LU0456855351.SGD","IE00BJTD4V19.USD","GOOGL","LU0466842654.USD","LU0494093205.USD","LU0175139822.USD","LU0557290698.USD","ADHD","LU0861579265.USD","IE00B775SV38.USD","BK4501","LU0965509010.AUD","BK4515","LU0128525689.USD","BK4512","LU0170899867.USD","IE00BJJMRY28.SGD","IE00BKVL7J92.USD","LU0149725797.USD","IE00BSNM7G36.USD","LU0056508442.USD","LU1803068979.SGD","LU0289961442.SGD","IE00BJJMRX11.SGD","LU0048573561.USD","BK4514","LU0719512351.SGD","BK4507","LU0320765059.SGD","AKLI","BK4077","LU1804176565.USD","LU0198837287.USD","LU0289941410.SGD","LU0052756011.USD","IE0004445015.USD","BK4170","LU1691799644.USD"],"gpt_icon":0},{"id":"2444489468","title":"Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2444489468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444489468?lang=en_us&edition=fundamental","pubTime":"2024-06-19 04:20","pubTimestamp":1718742000,"startTime":"0","endTime":"0","summary":"The prescription digital medicine company said that the FDA clearance positions EndeavorOTC as a scientifically and clinically validated digital therapy for adult ADHD patients.In a clinical study, 83% of study participants reported improvement in focus as measured by the test of variables of attention  control score.EndeavorOTC is Akili's second digital ADHD therapeutic product to receive FDA authorization, and is the only FDA-authorized digital therapeutic for ADHD available without a prescription, the company added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","AKLI","BK4139","ABVC","ADHD"],"gpt_icon":0},{"id":"2444468905","title":"Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game","url":"https://stock-news.laohu8.com/highlight/detail?id=2444468905","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444468905?lang=en_us&edition=fundamental","pubTime":"2024-06-19 04:01","pubTimestamp":1718740860,"startTime":"0","endTime":"0","summary":"Clinically proven to improve attention function, EndeavorOTC is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD. \"This FDA authorization of EndeavorOTC positions it as a scientifically and clinically validated digital therapy for adult ADHD patients, and we’re incredibly proud of pioneering a new tier of digital medicine,\" said Matt Franklin, Chief Executive Officer at Akili. \"This is the culmination of years of clinical studies and the collective effort of scores of technical, scientific, clinical, and regulatory professionals. We are particularly grateful to the patients who participated in the study that made this clearance possible.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gwk1uPiuHQ73ScTd9eaaBg--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/442ca9d6e0f378a0a858680888c75fa9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gwk1uPiuHQ73ScTd9eaaBg--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/442ca9d6e0f378a0a858680888c75fa9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akili-announces-fda-authorization-endeavorotc-200100445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","AKLI","BK4139","ADHD","ABVC"],"gpt_icon":0},{"id":"2439852099","title":"Akili Announces Merger Agreement and Recommends Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2439852099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2439852099?lang=en_us&edition=fundamental","pubTime":"2024-05-29 21:42","pubTimestamp":1716990169,"startTime":"0","endTime":"0","summary":"Akili (AKLI) has issued an announcement. On May 29, 2024, Akili, Inc. (“the Company”) announced entering into a Merger Agreement with Virtual Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akili-announces-merger-agreement-and-recommends-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akili-announces-merger-agreement-and-recommends-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKLI","BK4167"],"gpt_icon":0},{"id":"2439529687","title":"PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2439529687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2439529687?lang=en_us&edition=fundamental","pubTime":"2024-05-29 20:40","pubTimestamp":1716986459,"startTime":"0","endTime":"0","summary":"PureTech Health  said Wednesday that its founded entity, Akili, Inc. , a digital therapeutics company, and Virtual Therapeutics have signed a definitive merger agreement to form a diversified, digital health company.Under the terms of the deal, Akili shareholders will receive $0.4340 per share in cash, which represents a roughly 4% premium to Akili's closing stock price on Tuesday, and an approximately 85% premium to its closing price on April 29, the last trading day before Akili announced it was evaluating potential strategic alternatives.The merger, which was approved by Virtual Therapeutics' and Akili's board of directors, is expected to close in Q3 at which point Akili shares will no longer be listed on any public stock exchange. The combined organization will operate as privately held Virtual Therapeutics, with Akili operating as a wholly owned subsidiary.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKLI","BK4139","BK4167","PRTC","LENZ"],"gpt_icon":0},{"id":"2439352624","title":"Akili to Combine with Virtual Therapeutics in Go-Private Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2439352624","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2439352624?lang=en_us&edition=fundamental","pubTime":"2024-05-29 20:31","pubTimestamp":1716985860,"startTime":"0","endTime":"0","summary":"Akili and Virtual Therapeutics have agreed to merge in a go-private deal that will create a larger diversified digital health company.Shareholders of Akili, a digital therapeutics company, will receive 43.4 cents per share of common stock in cash according to the terms of the deal, the companies said Wednesday.Akili shares have been under pressure in 2024, falling about 14% and closing at 42 cents on Tuesday. Over the last 12 months, shares are down 66%. On Wednesday, the shares were halted in premarket trading.In a joint-statement, the two companies said that the price represents a 4% premium to Akili's closing stock price on Tuesday and about an 85% premium to the closing price on April 29, the last trading day before Akili's said it was considering potential strategic alternatives.Akili Chief Executive Matt Franklin said that the combination of Akili's mobile digital therapeutics with Virtual Therapeutics' portfolio of virtual reality-based mental health solutions and gaming experti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4167","AKLI"],"gpt_icon":0},{"id":"2439525862","title":"BRIEF-Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement To Establish Leading Digital Health Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2439525862","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2439525862?lang=en_us&edition=fundamental","pubTime":"2024-05-29 20:03","pubTimestamp":1716984220,"startTime":"0","endTime":"0","summary":"May 29  - Akili Inc   :   * VIRTUAL THERAPEUTICS, AKILI INTERACTIVE ENTER INTO DEFINITIVE MERGER AGREEMENT TO ESTABLISH LEADING DIGITAL HEALTH COMPANY   * AKILI INC: AKILI SHAREHOLDERS WILL RECEIVE $0.4340 PER SHARE OF COMMON STOCK IN CASH   * AKILI INC: UNDER TERMS OF AGREEMENT, AKILI SHAREHOLDERS WILL RECEIVE $0.4340 PER SHARE OF COMMON STOCK IN CASH   * AKILI INC: UPON COMPLETION OF TRANSACTION, AKILI'S COMMON STOCK WILL NO LONGER BE LISTED ON ANY PUBLIC STOCK EXCHANGE.   * AKILI INC: AKILI TO OPERATE AS WHOLLY OWNED SUBSIDIARY OF VIRTUAL THERAPEUTICS   * AKILI INC: FOLLOWING COMPLETION OF TRANSACTION, COMBINED ORGANIZATION WILL OPERATE AS VIRTUAL THERAPEUTICSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI","BK4139","BK4167","LENZ"],"gpt_icon":0},{"id":"2439652390","title":"Press Release: Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2439652390","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2439652390?lang=en_us&edition=fundamental","pubTime":"2024-05-29 20:00","pubTimestamp":1716984000,"startTime":"0","endTime":"0","summary":"Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company. Akili to operate as wholly owned subsidiary of Virtual Therapeutics. Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. , a leading digital therapeutics company, today announced the signing of a definitive merger agreement to form a diversified, leading digital health company.The transaction, approved by both of Virtual Therapeutics' and Akili's board of directors, is expected to close in the third quarter of 2024, subject to certain closing conditions, including the tender of a majority of Akili shares into a tender offer to be launched by Virtual Therapeutics and Akili having not less than a specified amount of cash-on-hand, dependi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI","BK4167","LENZ","BK4139"],"gpt_icon":0},{"id":"2435389639","title":"Akili reports Q1 results; suspends outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2435389639","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435389639?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:25","pubTimestamp":1715772354,"startTime":"0","endTime":"0","summary":"Akili press release : Q1 non-GAAP net loss was $9.3 million for the first quarter of 2024, compared to a non-GAAP net loss of $10.8 million for the fourth quarter of 2023. Revenue of $0.38M   misses by $0.41M. Cash and cash equivalents as of March 31, 2024, were $63.2 million compared to $75.2 million as of December 31, 2023.   Suspension of Guidance and Business Update As announced in late April 2024, the company’s board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. The board of directors’ evaluation is ongoing, and it expects to make an announcement regarding the outcome of its review upon completion. In light of the board of directors’ evaluation of potential strategic alternatives, the company will not provide financial guidance until further notice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4106380-akili-reports-q1-results-suspends-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4167","AKLI"],"gpt_icon":0},{"id":"2435525009","title":"Akili Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2435525009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435525009?lang=en_us&edition=fundamental","pubTime":"2024-05-15 05:01","pubTimestamp":1715720510,"startTime":"0","endTime":"0","summary":"* Akili Inc    reported a quarterly adjusted loss of 12 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -17 cents.  The lone an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI"],"gpt_icon":0},{"id":"2435523256","title":"Akili Q1 2024 Adj EPS $(0.12) Beats $(0.14) Estimate, Sales $383.00K Miss $794.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2435523256","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435523256?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:41","pubTimestamp":1715719300,"startTime":"0","endTime":"0","summary":"Akili (NASDAQ:AKLI) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38829882/akili-q1-2024-adj-eps-0-12-beats-0-14-estimate-sales-383-00k-miss-794-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI"],"gpt_icon":0},{"id":"2435528542","title":"Akili Reports First Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435528542","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435528542?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:01","pubTimestamp":1715716860,"startTime":"0","endTime":"0","summary":"Company announces full voluntary prepayment of debt and termination of Amended & Restated Loan and Security Agreement with Silicon Valley Bank. Following recent restructuring, focusing efforts primarily on supporting existing customers, executing the amended agreement with Shionogi, and evaluating potential strategic alternatives. BOSTON, May 14, 2024----Akili, Inc. , a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress.As announced in late April 2024, the Company’s board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. \"We are working expeditiously with our board of directors and our external advisors and look forward to providing an update on this process in the future when appropriate,\" said Matt Franklin, President and Chief Executive Officer at Akili.Total Operating Expenses: GAAP total operat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/J.tEBTcRZ7rY31PN1Dp_xg--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/3e9550502da7e3ddc0e05f0156600b55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/J.tEBTcRZ7rY31PN1Dp_xg--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/3e9550502da7e3ddc0e05f0156600b55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akili-reports-first-quarter-2024-200100044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","AKLI"],"gpt_icon":0},{"id":"2434989763","title":"Akili Inc    expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434989763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2434989763?lang=en_us&edition=fundamental","pubTime":"2024-05-11 06:00","pubTimestamp":1715378409,"startTime":"0","endTime":"0","summary":"* Akili Inc     is expected to show a rise in quarterly revenue when it reports  results on May 14 for the period ending March 31 2024   * The Boston Massachusetts-based  company is expected to report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI"],"gpt_icon":0},{"id":"2431322190","title":"BUZZ-Akili rises on plans to evaluate alternatives, reduce workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2431322190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2431322190?lang=en_us&edition=fundamental","pubTime":"2024-04-30 22:22","pubTimestamp":1714486944,"startTime":"0","endTime":"0","summary":"** Videogame-based therapy maker Akili's    shares rise 80% to $0.42   ** Company says it has started process to evaluate potential alternatives    ** Says workforce will be reduced by about 46%, including elimination of its marketing and medical affairs teams   ** AKLI announces amendment to its strategic distribution agreement with Japan-based Shionogi & Co      ** Under amended agreement, Shionogi has canceled long-term debt obligation of $5 mln   ** Akili to receive upfront payment of $10.5 mln in consideration for elimination of future royalty payments   ** Including session moves, stock down 22.4% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI","NEO","BK4121","BK4167","BUZZ","BK4196"],"gpt_icon":0},{"id":"2431322831","title":"Dow Tumbles 200 Points; McDonald's Posts Downbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2431322831","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2431322831?lang=en_us&edition=fundamental","pubTime":"2024-04-30 22:17","pubTimestamp":1714486674,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38522465/dow-tumbles-200-points-mcdonalds-posts-downbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI","AGBA","PCOM","MCD","VNCE","LICN","GMM","MED"],"gpt_icon":0},{"id":"2431418293","title":"Akili to Reduce Workforce by 46% as Board Considers Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2431418293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2431418293?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:22","pubTimestamp":1714479720,"startTime":"0","endTime":"0","summary":"Akili plans to reduce its workforce by 46% as its board evaluates potential strategic alternatives aimed at maximizing shareholder value.The digital medicine company said the reduction will include an elimination of its marketing and medical affairs teams. In conjunction with the restructuring, it will substantially reduce promotions for its EndeavorRx and EndeavorOTC products.Akili had 68 full-time employees as of Feb. 1, according to a regulatory filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKLI","BK4167"],"gpt_icon":0},{"id":"2431234961","title":"Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2431234961","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2431234961?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:00","pubTimestamp":1714478400,"startTime":"0","endTime":"0","summary":"Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation. Company announces exploration of strategic alternatives and associated workforce reduction. Company to release first quarter 2024 financial results on May 14, 2024. As a part of this evaluation of strategic alternatives, Akili announced today that its board of directors approved a revised operating plan and budget for the remainder of 2024 and related restructuring of the organization to lower operating expenses while focusing on supporting Shionogi’s regulatory and commercialization activities. The Company’s workforce will be reduced by approximately 46% including an elimination of the Company’s marketing and medical affairs teams. In conjunction with this restructuring, the Company has substantially reduced promotional activity for its EndeavorRx and EndeavorOTC products, but plans to continue to support current users of its products and make its products available for purchase. Additi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IWjaNNyjLyCgw0qURqS0Lw--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/f8d982bc61c6225db74934dc7e2d71d5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IWjaNNyjLyCgw0qURqS0Lw--~B/aD0xMjAwO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/f8d982bc61c6225db74934dc7e2d71d5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akili-announces-amended-agreement-shionogi-120000051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","BK4139","ABVC","AKLI"],"gpt_icon":0},{"id":"2429280541","title":"BRIEF-Akili Says Received Letter From Nasdaq, Granted Compliance Period Until October 21, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2429280541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2429280541?lang=en_us&edition=fundamental","pubTime":"2024-04-24 05:41","pubTimestamp":1713908506,"startTime":"0","endTime":"0","summary":"April 23 (Reuters) - Akili Inc   :   * AKILI - RECEIVED LETTER FROM NASDAQ, GRANTED COMPLIANCE PERIOD UNTIL OCTOBER 21, 2024  TO REGAIN COMPLIANCE WITH NASDAQ FOR CONTINUED LISTINGSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","NDAQ","BK4112",".IXIC","LU2095319765.USD","BK4167","BK4588","MNQmain","QQQ","LU2210149790.SGD","PSQ","QID","NQmain","TQQQ","SQQQ","AKLI","LU2210150020.SGD","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akiliinteractive.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":-0.0092},{"period":"1year","weight":-0.1479},{"period":"ytd","weight":-0.1131}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0014},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2555},{"period":"ytd","weight":0.2512}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.027616},{"month":2,"riseRate":1,"avgChangeRate":0.19175},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.091315},{"month":4,"riseRate":0.333333,"avgChangeRate":0.014235},{"month":5,"riseRate":0.666667,"avgChangeRate":0.051367},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.00519},{"month":7,"riseRate":0.5,"avgChangeRate":0.011682},{"month":8,"riseRate":0,"avgChangeRate":-0.245042},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.305332},{"month":10,"riseRate":0,"avgChangeRate":-0.126304},{"month":11,"riseRate":0.666667,"avgChangeRate":0.019807},{"month":12,"riseRate":0,"avgChangeRate":-0.084601}],"exchange":"NASDAQ","name":"Akili, Inc.","nameEN":"Akili, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akili, Inc.(AKLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akili, Inc.(AKLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akili, Inc.,AKLI,Akili, Inc.股票,Akili, Inc.股票老虎,Akili, Inc.股票老虎国际,Akili, Inc.行情,Akili, Inc.股票行情,Akili, Inc.股价,Akili, Inc.股市,Akili, Inc.股票价格,Akili, Inc.股票交易,Akili, Inc.股票购买,Akili, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akili, Inc.(AKLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akili, Inc.(AKLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}